Famotidine, lyophilizate 20 mg 5 pcs

Pharmacotherapeutic group

A gastric gland secretion reducing agent – H<SUB>2</SUB>-histamine receptor blocker

Pharmacological action

Histamine H₂-receptor blocker of III generation. Suppresses the production of hydrochloric acid, both basal and stimulated by histamine, gastrin and to a lesser extent acetylcholine. Simultaneously with reduction of hydrochloric acid production and increase in pH it reduces pepsin activity. The duration of action with single administration depends on the dose and varies from 12 to 24 hours.

Indications

Active ingredient

Composition

Lyophilizate – 1 fl.:

Lyophilisate for the preparation of solution for intravenous injection, 20 mg.

How to take, the dosage

Individual, depending on indications.

Inhaled for the purpose of treatment, 10-20 mg 2 times a day or 40 mg once a day. If necessary, the daily dose can be increased to 80-160 mg. For prophylaxis, use 20 mg 1 time per day before going to bed.

In case of intravenous injection, the single dose is 20 mg, the interval between the injections is 12 hours.

In patients with a CKR less than 30 ml/min or with a serum creatinine concentration greater than 3 mg/dL, it is recommended that the dose be reduced to 20 mg/day.

Interaction

Concomitant use with anticoagulants does not exclude the possibility of increasing prothrombin time and bleeding.

In concomitant use with antacids containing magnesium hydroxide and aluminum hydroxide, absorption of famotidine may be reduced.

Concomitant use with itraconazole may decrease the plasma concentration of itraconazole and reduce its effectiveness.

In concomitant use with nifedipine there has been a case of decrease of cardiac output and cardiac output, probably due to increased negative inotropic effect of nifedipine.

Concomitant use with norfloxacin decreases plasma concentration of norfloxacin; with probenecid increases plasma concentration of famotidine.

In concomitant use there has been described a case of increased plasma concentration of phenytoin with risk of developing toxic effects.

The bioavailability of cefpodoxime decreases with concomitant use, probably due to its decreased gastric solubility when the pH of gastric juice is increased by famotidine.

When used concomitantly with cyclosporine, there may be some increase in plasma concentration of cyclosporine.

Special Instructions

With caution use in patients with impaired renal and hepatic function.

Before starting treatment, the possibility of malignant disease of the esophagus, stomach or duodenum should be excluded.

It does not change the activity of microsomal liver enzymes.

The interval between intake of antacids and famotidine should be at least 1-2 hours.

Clinical experience with famotidine in children is limited.

Cautious use in patients with renal dysfunction.

Cautious use in patients with impaired liver function.

Clinical experience with famotidine in children is limited.

Contraindications

Side effects

Digestive system disorders: lack of appetite, dry mouth, taste disorders, nausea, vomiting, abdominal distension, diarrhea or constipation; in some cases – development of cholestatic jaundice, increased level of transaminases in blood plasma.

CNS disorders: headache, increased fatigue, tinnitus, transient mental disorders are possible.

Cardiovascular system disorders: rarely – arrhythmias.

Hematopoietic system: very rarely – agranulocytosis, pancytopenia, leukopenia, thrombocytopenia.

Muscular system disorders: muscle pain and joint pain may occur.

Allergic reactions: skin itching, bronchospasm, fever are possible.

Dermatological reactions: alopecia, common acne, dry skin are possible.

Local reactions: irritation at the injection site.

Pregnancy use

It is contraindicated in pregnancy and lactation.

Famotidine is excreted with breast milk.

Similarities